Literature DB >> 7355534

Primary adenocarcinoma of bladder.

W A Jones, R P Gibbons, R J Correa, K B Cummings, J T Mason.   

Abstract

Since 1959, 10 patients with primary adenocarcinoma of the bladder were treated at the Virginia Mason Medical Center for an incidence of 1.5 per cent of all bladder cancers. This retrospective study shows that histologic grade and tumor location had a variable influence on survival whereas clinical stage appeared to have a direct effect on survival. The only long-term survivors were the 4 low-stage patients who underwent radical cystectomy.

Entities:  

Mesh:

Year:  1980        PMID: 7355534     DOI: 10.1016/0090-4295(80)90400-8

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  Clinical features of urachal carcinoma in Japan: review of 157 patients.

Authors:  M Ghazizadeh; S Yamamoto; K Kurokawa
Journal:  Urol Res       Date:  1983

2.  Primary adenocarcinomas of the human urinary bladder: histochemical, immunological and ultrastructural studies.

Authors:  J Alroy; D Roganovic; B F Banner; J B Jacobs; F B Merk; A A Ucci; P W Kwan; J S Coon; A W Miller
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1981

3.  Urachal mucinous tumor of uncertain malignant potential: a case report.

Authors:  Jung-Woo Choi; Ju-Han Lee; Young-Sik Kim
Journal:  Korean J Pathol       Date:  2012-02-23

4.  Complex mucinous cystadenoma of undetermined malignant potential of the urachus.

Authors:  Andrew J Schell; Curtis J Nickel; Phillip A Isotalo
Journal:  Can Urol Assoc J       Date:  2009-08       Impact factor: 1.862

Review 5.  Treatment of superficial bladder cancer.

Authors:  A Morales
Journal:  Can Med Assoc J       Date:  1980-05-24       Impact factor: 8.262

6.  Primary bladder adenocarcinoma versus metastatic colorectal adenocarcinoma: a persisting diagnostic challenge.

Authors:  Somak Roy; Matthew A Smith; Kathy M Cieply; Marie B Acquafondata; Anil V Parwani
Journal:  Diagn Pathol       Date:  2012-11-02       Impact factor: 2.644

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.